

For Immediate Release:
November 21, 2014

Media Contact:
Katie Kiley Brown, NCCN
215.690.0238
brown@nccn.org

Changing the Course of Prostate Cancer Treatment: Life Expectancy Estimation, Active Surveillance, and Drug Development

NCCN has published the 20th annual edition of the NCCN Guidelines® for Prostate Cancer, one of the eight original NCCN Guidelines published in November 1996.

FORT WASHINGTON, PA—The [National Comprehensive Cancer Network® \(NCCN®\)](#) has published the 20th annual edition of the [NCCN Clinical Practice Guidelines in Oncology \(NCCN Guidelines®\)](#) for Prostate Cancer—one of the eight original NCCN Guidelines® published in November 1996.

“We have made an incredible amount of progress in the diagnosis and treatment of prostate cancer since the NCCN Guidelines were published in 1996,” said James L. Mohler, MD, Associate Director for Translational Research, Chair, Department of Urology, and Professor of Oncology, [Roswell Park Cancer Institute](#); and NCCN Guidelines Panel Chair for Prostate Cancer. “The death rate for men with prostate cancer has fallen from approximately 40,000 to 29,000ⁱ, and the evolution of the NCCN Guidelines for Prostate Cancer has contributed significantly to that trend.”

Dr. Mohler, who has been a member of the NCCN Guidelines Panels for Prostate Cancer and Prostate Cancer Early Detection since 2005 and 2003, respectively, notes that life expectancy estimation for men with prostate cancer has had a transformative effect on treatment. Today, NCCN Guidelines recommendations for early detection and treatment consider life expectancy, which can be derived from prediction tables and adjusted based upon patients’ comorbidities and other factors.

“The sole recommendation of active surveillance for men with low risk and very low risk prostate cancer, although initially controversial, has been gaining increased acceptance as more clinical experience supports the action taken by the NCCN Prostate Guidelines Panel,” said Dr. Mohler.

Changing the Course of Prostate Cancer Treatment: Life Expectancy Estimation, Active Surveillance, and Drug Development

According to Dr. Mohler, significant innovations have also been made in the treatment of metastatic castration-recurrent prostate cancer (CRPC), improving outcomes and presenting men and their physicians with an armamentarium of agents from which to tailor treatment.

Today, NCCN develops and maintains 60 NCCN Guidelines, covering 97% of malignant cancers. The NCCN Guidelines are developed and updated through an evidence-based process in which the expert panels integrate comprehensive clinical and scientific data with the judgment of the multidisciplinary panel members and other experts drawn from [NCCN Member Institutions](#). Access to the complete library of NCCN Guidelines is available free-of-charge at [NCCN.org](#).

“NCCN applauds and thanks the NCCN Guidelines Panel for Prostate Cancer,” said Robert W. Carlson, MD, Chief Executive Officer, NCCN. “Given the challenge of determining the optimal treatment for the most commonly diagnosed cancer in men in the United States, our panel members over the past 20 years have consistently served in the best interest of men with prostate cancer.”

On March 12 – 14, 2015, NCCN will host its [20th Annual Conference: Advancing the Standard of Cancer Care™](#) at The Diplomat in Hollywood, Florida. In recognition of its [20th anniversary](#), NCCN will host a special live roundtable during the conference comprised of NCCN leadership—past and present—as well as other stakeholders who have had a significant impact on the development, progression, and success of NCCN over the years. Noteworthy historical NCCN accomplishments and events will be discussed, as well as the impact NCCN has had and continues to have on the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.

To learn more about NCCN, the NCCN Guidelines, and the NCCN 20th Annual Conference, visit [NCCN.org](#).

###

About the National Comprehensive Cancer Network

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 25 of the world’s leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous

Changing the Course of Prostate Cancer Treatment: Life Expectancy Estimation, Active Surveillance, and Drug Development

stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.

The NCCN Member Institutions are: Fred and Pamela Buffett Cancer Center at The Nebraska Medical Center, Omaha, NE; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.

Clinicians, visit NCCN.org. Patients and caregivers, visit NCCN.org/patients.

ⁱ National Comprehensive Cancer Network®, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®); Prostate Cancer, Version 1.2015. http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf